Proliferating Cell Nuclear Antigen (PCNA) Expression in Chronic Lymphocytic Leukemia (CLL)

Auro del Giglio(Faculdade de Medicina do ABC), Albert Deisseroth(National Cancer Institute), Hideyuki Saya(Fujita Health University Hospital), Susan O’Brien(University of California, Irvine), Dalton F. Chamone(The University of Texas MD Anderson Cancer Center), R. Ford(Fermi National Accelerator Laboratory), Dennis A. Johnston, John T. Manning(The University of Texas Medical Branch at Galveston), Michael J. Keating(The University of Texas MD Anderson Cancer Center)
Leukemia & lymphoma/Leukemia and lymphoma
January 1, 1993
10.3109/10428199309148548
Cited by 26

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k